SG Americas Securities Boosts Stake in Edgewise Therapeutics

Institutional investor increases position in biotech firm by nearly 800%

Apr. 5, 2026 at 8:43am

Got story updates? Submit your updates here. ›

SG Americas Securities LLC significantly increased its stake in Edgewise Therapeutics, Inc. (NASDAQ: EWTX) during the fourth quarter, acquiring an additional 78,842 shares to bring its total holdings to 88,723 shares, or approximately 0.08% of the company's outstanding stock.

Why it matters

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases, particularly in the areas of kidney disorders and neuromuscular diseases. The increase in SG Americas' position suggests the institutional investor sees significant potential in the company's pipeline and future prospects.

The details

According to a recent 13F filing, SG Americas Securities increased its position in Edgewise Therapeutics by 797.9% during the fourth quarter. The firm now owns 88,723 shares of the company's stock, valued at approximately $2.2 million as of the most recent filing. This represents a substantial increase from the 9,881 shares the firm held at the end of the third quarter.

  • SG Americas Securities filed its 13F report for the fourth quarter on April 5, 2026.
  • The firm increased its Edgewise Therapeutics position during the fourth quarter of 2025.

The players

SG Americas Securities LLC

An institutional investment firm that manages a diverse portfolio of equity and fixed-income securities.

Edgewise Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for rare diseases, particularly in the areas of kidney disorders and neuromuscular diseases.

Got photos? Submit your photos here. ›

The takeaway

The significant increase in SG Americas' position in Edgewise Therapeutics suggests the institutional investor sees strong potential in the company's pipeline and future growth prospects, underscoring the biotech firm's importance in the rare disease treatment landscape.